A Randomized Phase II Study of INC280 capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplified Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05642572

Study #:
STUDY00150670

Start Date:
Oct 29, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05642572

View Complete Trial Details & Eligibility at ClinicalTrials.gov